MOUNTAIN VIEW, Calif., Dec. 13, 2011 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued a final guidance which determined that Novartis AG's drug Lucentis is not as cost effective as conventional laser photocoagulation treatment and rejected the leading drug therapy as a treatment for diabetic macular edema (DME), a swelling of retinal tissue and the most common cause of vision loss in diabetics. The rejection means that the UK National Health Service (NHS) currently will not pay for drug therapy with Lucentis for DME treatment in diabetic patients, thereby creating another important opportunity for advanced laser treatments such as IRIDEX' MicroPulse laser therapy, which has shown to be as effective as conventional laser photocoagulation with no associated retina tissue damage.
NICE, an independent appraisal committee which the UK NHS relies upon, determined that the benefits derived by Lucentis do not justify its cost; and that laser photocoagulation represented better value for NHS resources. "While Novartis is certain to appeal the ruling, this is an important indication that DME patients should consider other options besides drug therapy," noted Dominik Beck, PhD., IRIDEX President and CEO.
"This is a very clear and important statement by one of the most important medical care payers in the world: drugs are not a panacea for retinal diseases," Dr. Beck said. "Drugs like Lucentis certainly have a role in ophthalmology and can be an excellent and safe treatment for acute DME, but in addition to high costs, they come with side effects and questions about their long term benefits. That's among the reasons why we now offer MicroPulse technology on all of our new laser systems and why MicroPulse technology should be considered a first line treatment for most forms of DME. Numerous recent studies show that MicroPulse technology can provide significant durable benefits for diabetes patients without damaging the retina; thus providing powerful economic advantages for both the payors and patients."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV